Jimmy Yee
Interventional Cardiology · Bellingham, WANPI 1386040616
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,892 of the $5,331 with a category attached, or 73.0%. 11 manufacturers reported payments, led by Abbott at 48.2% of the total. Reporting peaked in 2019 at $4,356 and has fallen 96.8% since, to $138 in 2025.
Across 40 payments — averaging $133.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- Medtronic$557
- Heartflow, Inc.$257
- Shockwave Medical, Inc$153
- Abiomed$124
- plus $171 from 5 others
What the payments were for
- Travel & lodging$3,89273%
- Food & beverage$1,43927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $2,567 |
| Boston Scientific | 9 | $1,502 |
| Medtronic(2 entities) | 6 | $557 |
| Heartflow, Inc. | 4 | $257 |
| Shockwave Medical, Inc | 2 | $153 |
| Abiomed | 1 | $124 |
| Cardiva Medical, Inc. | 1 | $96 |
| Terumo Medical Corporation | 1 | $24 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$2,189
- ANGIOJET$1,105
- Resolute$324
- MitraClip$138
- FFRct$134
- Impella$124
- AVVIGO Guidance System$102
How this compares
$5,331 in reported general payments places this provider in the 55th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $266,915 |
| JardianceEmpagliflozin | 84 | $91,491 |
| EntrestoSacubitril/Valsartan | 41 | $58,011 |
| XareltoRivaroxaban | 34 | $41,779 |
| BrilintaTicagrelor | 44 | $36,653 |
| Repatha SureclickEvolocumab | 26 | $35,922 |
| Metoprolol Succinate | 666 | $8,774 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $7,319 |
| Atorvastatin Calcium | 405 | $6,276 |
| Praluent PenAlirocumab | 11 | $6,238 |
| Ranolazine ErRanolazine | 48 | $4,769 |
| ClopidogrelClopidogrel Bisulfate | 150 | $2,735 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 190 | $2,701 |
| Prasugrel Hcl | 42 | $2,656 |
| Carvedilol | 267 | $2,521 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Bellingham
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
- Mohit JainSpokane$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.